Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men

Jane McEneny, Peter A McPherson, Ann McGinty, Stephen S Hull, David R McCance, Ian S Young

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background

The worldwide epidemic of obesity is a major public health concern and is persuasively linked to the rising prevalence of diabetes and cardiovascular disease. Obesity is often associated with an abnormal lipoprotein profile, which may be partly negated by pioglitazone intervention, as this can influence the composition and oxidation characteristics of low-density lipoprotein (LDL). However, as pioglitazone's impact on these parameters within high-density lipoprotein (HDL), specifically HDL2&3, is absent from the literature, this study was performed to address this shortcoming.

Methods

Twenty men were randomized to placebo or pioglitazone (30 mg/day) for 12 weeks. HDL2&3 were isolated by rapidultracentrifugation. HDL2&3-cholesterol and phospholipid content were assessed by enzymatic assays and apolipoprotein AI (apoAI) content by single-radial immunodiffusion. HDL2&3 oxidation characteristics were assessed by monitoring conjugated diene production and paraoxonase-1 activity by spectrophotometric assays.

Results

Compared with the placebo group, pioglitazone influenced the composition and oxidation potential of HDL2&3. Specifically, total cholesterol (P < 0.05), phospholipid (P < 0.001) and apoAI (P < 0.001) were enriched within HDL2. Furthermore, the resistance of HDL2&3 to oxidation (P < 0.05) and the activity of paroxonase-1 were also increased (P < 0.001).

Conclusions

Overall, these findings indicate that pioglitazone treatment induced antiatherogenic changes within HDL2&3, which may help reduce the incidence of premature cardiovascular disease linked with obesity.

Original languageEnglish
Pages (from-to)20-24
JournalAnnals of Clinical Biochemistry
Volume50
Issue number1
Early online date12 Nov 2012
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Adult
  • Apolipoprotein A-I
  • Aryldialkylphosphatase
  • Body Mass Index
  • Cardiovascular Diseases
  • Cholesterol, HDL
  • Fasting
  • Humans
  • Hypoglycemic Agents
  • Immunodiffusion
  • Male
  • Middle Aged
  • Obesity
  • Oxidation-Reduction
  • Spectrophotometry
  • Thiazolidinediones
  • Ultracentrifugation

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men'. Together they form a unique fingerprint.

  • Cite this